Compare Stocks: RCUS, SMMT, MDGL, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$57.18 -2.2%	$64.13	$49.26 ▼ $70.98	$11.31B	0.22	1.91 million shs	2.19 million shs
MDGL Madrigal Pharmaceuticals	$499.40 -0.1%	$523.18	$393.61 ▼ $615.00	$11.55B	-1.04	221,280 shs	289,230 shs
RCUS Arcus Biosciences	$24.43 -3.2%	$27.83	$13.21 ▼ $31.74	$3.21B	0.94	1.72 million shs	1.04 million shs
SMMT Summit Therapeutics	$16.75 +0.4%	$15.11	$12.07 ▼ $29.23	$13.31B	-1.51	7.17 million shs	5.19 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-2.16%	-5.11%	-14.62%	-3.07%	+4.23%
MDGL Madrigal Pharmaceuticals	-0.06%	-3.32%	-8.69%	-5.43%	+11.19%
RCUS Arcus Biosciences	-3.02%	-1.97%	-18.53%	-19.70%	+81.28%
SMMT Summit Therapeutics	+0.36%	+7.30%	+14.73%	+8.63%	-18.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$57.18 -2.2%	$64.13	$49.26 ▼ $70.98	$11.31B	0.22	1.91 million shs	2.19 million shs
MDGL Madrigal Pharmaceuticals	$499.40 -0.1%	$523.18	$393.61 ▼ $615.00	$11.55B	-1.04	221,280 shs	289,230 shs
RCUS Arcus Biosciences	$24.43 -3.2%	$27.83	$13.21 ▼ $31.74	$3.21B	0.94	1.72 million shs	1.04 million shs
SMMT Summit Therapeutics	$16.75 +0.4%	$15.11	$12.07 ▼ $29.23	$13.31B	-1.51	7.17 million shs	5.19 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-2.16%	-5.11%	-14.62%	-3.07%	+4.23%
MDGL Madrigal Pharmaceuticals	-0.06%	-3.32%	-8.69%	-5.43%	+11.19%
RCUS Arcus Biosciences	-3.02%	-1.97%	-18.53%	-19.70%	+81.28%
SMMT Summit Therapeutics	+0.36%	+7.30%	+14.73%	+8.63%	-18.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.67	Moderate Buy	$89.17	55.95% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$710.20	42.21% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	56.80% Upside
SMMT Summit Therapeutics	2.53	Moderate Buy	$28.61	70.79% Upside

Current Analyst Ratings Breakdown

Latest RCUS, SMMT, MDGL, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	SMMT Summit Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/30/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/30/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$43.00
9/29/2026	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$41.00
9/29/2026	SMMT Summit Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform
9/29/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
9/25/2026	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $43.00
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$704.00
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$704.00
9/23/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/23/2026	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Buy	$725.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.41B	3.25	$2.79 per share	20.48	$31.68 per share	1.80
MDGL Madrigal Pharmaceuticals	$1.28B	8.99	N/A	N/A	$26.54 per share	18.82
RCUS Arcus Biosciences	$117M	26.58	N/A	N/A	$5.84 per share	4.18
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	154.54	10.55	0.42	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	89.98	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest RCUS, SMMT, MDGL, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/27/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8769	N/A	N/A	N/A	$11.14 million	N/A
10/26/2026	Q3 2026	BMRN BioMarin Pharmaceutical	$1.34	N/A	N/A	N/A	$1.02 billion	N/A
10/19/2026	Q3 2026	SMMT Summit Therapeutics	-$0.28	N/A	N/A	N/A	$0.07 million	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
RCUS Arcus Biosciences	0.22	3.82	3.82
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
MDGL Madrigal Pharmaceuticals	98.50%
RCUS Arcus Biosciences	92.89%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
MDGL Madrigal Pharmaceuticals	17.60%
RCUS Arcus Biosciences	7.60%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable

RCUS, SMMT, MDGL, and BMRN Headlines

Recent News About These Companies

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

October 2 at 12:07 AM | finance.yahoo.com

Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab

October 2 at 2:06 PM | rttnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Climb 7.1% - Here's What Happened

October 2 at 7:21 AM | americanbankingnews.com

Summit agrees to $2 billion AstraZeneca equity investment

October 2 at 6:02 AM | americanbankingnews.com

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

October 2 at 2:30 AM | businesswire.com

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

October 2 at 2:30 AM | businesswire.com

What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?

October 1 at 7:45 PM | finance.yahoo.com

AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

September 30 at 12:52 PM | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)

September 30 at 12:52 PM | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?

September 30 at 12:20 PM | marketbeat.com

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

September 30 at 11:17 AM | 247wallst.com

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

September 30 at 1:03 AM | finance.yahoo.com

Summit Therapeutics PLC ADR (SMMT)

September 30 at 1:03 AM | ca.investing.com

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

September 29, 2026 | zacks.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?

September 29, 2026 | marketbeat.com

Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals

September 29, 2026 | invezz.comI

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal

September 29, 2026 | proactiveinvestors.com

AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up

September 28, 2026 | rttnews.com

Summit Therapeutics rises after AstraZeneca commits $2B investment

September 28, 2026 | msn.com

Summit shares surge after-hours on $2 billion AstraZeneca equity deal

September 28, 2026 | finance.yahoo.com

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

September 28, 2026 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, SMMT, MDGL, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$57.18 -1.26 (-2.16%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$57.18 -0.01 (-0.01%)

As of 10/2/2026 07:30 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$499.40 -0.31 (-0.06%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$499.49 +0.09 (+0.02%)

As of 10/2/2026 07:30 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$24.43 -0.80 (-3.19%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$24.51 +0.08 (+0.34%)

As of 10/2/2026 07:30 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Summit Therapeutics NASDAQ:SMMT

$16.75 +0.06 (+0.36%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$16.80 +0.05 (+0.27%)

As of 10/2/2026 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, SMMT, MDGL, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, SMMT, MDGL, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, SMMT, MDGL, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, SMMT, MDGL, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Madrigal Pharmaceuticals NASDAQ:MDGL

Arcus Biosciences NYSE:RCUS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, SMMT, MDGL, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, SMMT, MDGL, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, SMMT, MDGL, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, SMMT, MDGL, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Madrigal Pharmaceuticals NASDAQ:MDGL

Arcus Biosciences NYSE:RCUS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools